Rapamycin, by Inhibiting mTORC1 Signaling, Prevents the Loss of Striatal Bidirectional Synaptic Plasticity in a Rat Model of L-DOPA-Induced Dyskinesia

Levodopa (L-DOPA) treatment is the main gold-standard therapy for Parkinson’s disease (PD). Besides good antiparkinsonian effects, prolonged use of this drug is associated to the development of involuntary movements known as L-DOPA-induced dyskinesia (LID). LID is linked to a sensitization of dopami...

Full description

Saved in:

Bibliographic Details
Published in:	Frontiers in aging neuroscience Vol. 12; p. 230
Main Authors:	Calabrese, Valeria, Di Maio, Anna, Marino, Gioia, Cardinale, Antonella, Natale, Giuseppina, De Rosa, Arianna, Campanelli, Federica, Mancini, Maria, Napolitano, Francesco, Avallone, Luigi, Calabresi, Paolo, Usiello, Alessandro, Ghiglieri, Veronica, Picconi, Barbara
Format:	Journal Article
Language:	English
Published:	Lausanne Frontiers Research Foundation 11.08.2020 Frontiers Media S.A
Subjects:	Aging Animal models Basal ganglia Behavior Behavioral plasticity Caudate-putamen Central nervous system diseases DARPP-32 protein depotentiation Dihydroxyphenylalanine Dopamine D1 receptors dorsolateral striatum Dyskinesia Experiments Extracellular signal-regulated kinase functional plasticity Glutamate receptors Glutamic acid receptors (ionotropic) Kinases Laboratories Levodopa levodopa-induced dyskinesia Movement disorders N-Methyl-D-aspartic acid receptors Neostriatum Neurodegenerative diseases Neuroscience Neurosciences Older people Parkinson's disease Phosphorylation Protein kinase A Proteins Rapamycin Rodents Signal transduction Surgery Synapses Synaptic plasticity TOR protein α-Amino-3-hydroxy-5-methyl-4-isoxazole propionic acid α-Amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptors
ISSN:	1663-4365, 1663-4365
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!